SuperUROP

Subterms

    Latest story

    188 Shares129 Views

    MIT-Takeda Program wraps up with 16 publications, a patent, and nearly two dozen projects completed

    by

    When the Takeda Pharmaceutical Co. and the MIT School of Engineering launched their collaboration focused on artificial intelligence in health care and drug development in February 2020, society was on the cusp of a globe-altering pandemic and AI was far from the buzzword it is today.As the program concludes, the world looks very different. AI has become a transformative technology across industries including health care and pharmaceuticals, while the pandemic has altered the way many businesses approach health care and changed how they develop and sell medicines.For both MIT and Takeda, the program has been a game-changer.When it launched, the collaborators hoped the program would help solve tangible, real-world problems. By its end, the program has yielded a catalog of new research papers, discoveries, and lessons learned, including a patent for a system that could improve the manufacturing of small-molecule medicines.Ultimately, the program allowed both entities to create a foundation for a world where AI and machine learning play a pivotal role in medicine, leveraging Takeda’s expertise in biopharmaceuticals and the MIT researchers’ deep understanding of AI and machine learning.“The MIT-Takeda Program has been tremendously impactful and is a shining example of what can be accomplished when experts in industry and academia work together to develop solutions,” says Anantha Chandrakasan, MIT’s chief innovation and strategy officer, dean of the School of Engineering, and the Vannevar Bush Professor of Electrical Engineering and Computer Science. “In addition to resulting in research that has advanced how we use AI and machine learning in health care, the program has opened up new opportunities for MIT faculty and students through fellowships, funding, and networking.”What made the program unique was that it was centered around several concrete challenges spanning drug development that Takeda needed help addressing. MIT faculty had the opportunity to select the projects based on their area of expertise and general interest, allowing them to explore new areas within health care and drug development.“It was focused on Takeda’s toughest business problems,” says Anne Heatherington, Takeda’s research and development chief data and technology officer and head of its Data Sciences Institute.“They were problems that colleagues were really struggling with on the ground,” adds Simon Davies, the executive director of the MIT-Takeda Program and Takeda’s global head of statistical and quantitative sciences. Takeda saw an opportunity to collaborate with MIT’s world-class researchers, who were working only a few blocks away. Takeda, a global pharmaceutical company with global headquarters in Japan, has its global business units and R&D center just down the street from the Institute.As part of the program, MIT faculty were able to select what issues they were interested in working on from a group of potential Takeda projects. Then, collaborative teams including MIT researchers and Takeda employees approached research questions in two rounds. Over the course of the program, collaborators worked on 22 projects focused on topics including drug discovery and research, clinical drug development, and pharmaceutical manufacturing. Over 80 MIT students and faculty joined more than 125 Takeda researchers and staff on teams addressing these research questions.The projects centered around not only hard problems, but also the potential for solutions to scale within Takeda or within the biopharmaceutical industry more broadly.Some of the program’s findings have already resulted in wider studies. One group’s results, for instance, showed that using artificial intelligence to analyze speech may allow for earlier detection of frontotemporal dementia, while making that diagnosis more quickly and inexpensively. Similar algorithmic analyses of speech in patients diagnosed with ALS may also help clinicians understand the progression of that disease. Takeda is continuing to test both AI applications.Other discoveries and AI models that resulted from the program’s research have already had an impact. Using a physical model and AI learning algorithms can help detect particle size, mix, and consistency for powdered, small-molecule medicines, for instance, speeding up production timelines. Based on their research under the program, collaborators have filed for a patent for that technology.For injectable medicines like vaccines, AI-enabled inspections can also reduce process time and false rejection rates. Replacing human visual inspections with AI processes has already shown measurable impact for the pharmaceutical company.Heatherington adds, “our lessons learned are really setting the stage for what we’re doing next, really embedding AI and gen-AI [generative AI] into everything that we do moving forward.”Over the course of the program, more than 150 Takeda researchers and staff also participated in educational programming organized by the Abdul Latif Jameel Clinic for Machine Learning in Health. In addition to providing research opportunities, the program funded 10 students through SuperUROP, the Advanced Undergraduate Research Opportunities Program, as well as two cohorts from the DHIVE health-care innovation program, part of the MIT Sandbox Innovation Fund Program.Though the formal program has ended, certain aspects of the collaboration will continue, such as the MIT-Takeda Fellows, which supports graduate students as they pursue groundbreaking research related to health and AI. During its run, the program supported 44 MIT-Takeda Fellows and will continue to support MIT students through an endowment fund. Organic collaboration between MIT and Takeda researchers will also carry forward. And the programs’ collaborators are working to create a model for similar academic and industry partnerships to widen the impact of this first-of-its-kind collaboration.  More

    More stories

    • 50 Shares149 Views

      in Data Management & Statistics

      Driving toward data justice

      by

      As a person with a mixed-race background who has lived in four different cities, Amelia Dogan describes her early life as “growing up in a lot of in-betweens.” Now an MIT senior, she continues to link different perspectives together, working at the intersection of urban planning, computer science, and social justice.

      Dogan was born in Canada but spent her high school years in Philadelphia, where she developed a strong affinity for the city.  

      “I love Philadelphia to death,” says Dogan. “It’s my favorite place in the world. The energy in the city is amazing — I’m so sad I wasn’t there for the Super Bowl this year — but it is a city with really big disparities. That drives me to do the research that I do and shapes the things that I care about.”

      Dogan is double-majoring in urban science and planning with computer science and in American studies. She decided on the former after participating in the pre-orientation program offered by the Department of Urban Studies and Planning, which provides an introduction to both the department and the city of Boston. She followed that up with a UROP research project with the West Philadelphia Landscape Project, putting together historical census data on housing and race to find patterns for use in community advocacy.

      After taking WGS.231 (Writing About Race), a course offered by the Program in Women’s and Gender Studies, her first year at MIT, Dogan realized there was a lot of crosstalk between urban planning, computer science, and the social sciences.

      “There’s a lot of critical social theory that I want to have background in to make me a better planner or a better computer scientist,” says Dogan. “There’s also a lot of issues around fairness and participation in computer science, and a lot of computer scientists are trying to reinvent the wheel when there’s already really good, critical social science research and theory behind this.”

      Data science and feminism

      Dogan’s first year at MIT was interrupted by the onset of the Covid-19 pandemic, but there was a silver lining. An influx of funding to keep students engaged while attending school virtually enabled her to join the Data + Feminism Lab to work on a case study examining three places in Philadelphia with historical names that were renamed after activist efforts.

      In her first year at MIT, Dogan worked several UROPs to hone her own skills and find the best research fit. Besides the West Philadelphia Land Project, she worked on two projects within the MIT Sloan School of Management. The first involved searching for connections between entrepreneurship and immigration among Fortune 500 founders. The second involved interviewing warehouse workers and writing a report on their quality of life.

      Dogan has now spent three years in the Data + Feminism Lab under Associate Professor Catherine D’Ignazio, where she is particularly interested in how technology can be used by marginalized communities to invert historical power imbalances. A key concept in the lab’s work is that of counterdata, which are produced by civil society groups or individuals in order to counter missing data or to challenge existing official data.

      Most recently, she completed a SuperUROP project investigating how femicide data activist organizations use social media. She analyzed 600 social media posts by organizations across the U.S. and Canada. The work built off the lab’s greater body of work with these groups, which Dogan has contributed to by annotating news articles for machine-learning models.

      “Catherine works a lot at the intersection of data issues and feminism. It just seemed like the right fit for me,” says Dogan. “She’s my academic advisor, she’s my research advisor, and is also a really good mentor.”

      Advocating for the student experience

      Outside of the classroom, Dogan is a strong advocate for improving the student experience, particularly when it intersects with identity. An executive board member of the Asian American Initiative (AAI), she also sits on the student advisory council for the Office of Minority Education.

      “Doing that institutional advocacy has been important to me, because it’s for things that I expected coming into college and had not come in prepared to fight for,” says Dogan. As a high schooler, she participated in programs run by the University of Pennsylvania’s Pan-Asian American Community House and was surprised to find that MIT did not have an equivalent organization.

      “Building community based upon identity is something that I’ve been really passionate about,” says Dogan. “For the past two years, I’ve been working with AAI on a list of recommendations for MIT. I’ve talked to alums from the ’90s who were a part of an Asian American caucus who were asking for the same things.”

      She also holds a leadership role with MIXED @ MIT, a student group focused on creating space for mixed-heritage students to explore and discuss their identities.

      Following graduation, Dogan plans to pursue a PhD in information science at the University of Washington. Her breadth of skills has given her a range of programs to choose from. No matter where she goes next, Dogan wants to pursue a career where she can continue to make a tangible impact.

      “I would love to be doing community-engaged research around data justice, using citizen science and counterdata for policy and social change,” she says. More